Cocrystal Pharma, Inc. (COCP) Q3 Net Loss Rises to $3.4M; Phase 1b Dosing Complete
Cocrystal Pharma reported a Q3 2026 net loss of $3.4M, up from $2.0M a year ago, with $105K in revenue. The company completed Phase 1b dosing for its CDI-988 norovirus study, with preliminary efficacy results expected in late 2026.
How this was made
The 30-second read
Why it matters
The earnings miss and trial progress are material for the stock, but the small scale limits broader market impact.
Market read
Micro‑cap biotech news with modest trading relevance; primary interest for specialty investors.
What to watch
Grants and modest revenue indicate some external support; cash burn may be mitigated by future financing.
Background
Cocrystal Pharma disclosed its Q3 earnings and trial update via a GlobeNewswire press release.
Ticker impact
Q3 2026 net loss of $3.4M reported and Phase 1b dosing completed for CDI-988 norovirus study.
likely downward pressure as investors digest higher loss and cash constraints.
Quarterly loss is higher YoY and cash runway is limited; no new revenue streams announced.
Market effects
Limited impact on broader biotech sector; highlights early‑stage trial risk.
Primarily U.S. micro‑cap investors; no broader regional effect.
Minimal global relevance beyond niche biotech investors.
Counterpoint
Potential upside if Phase 1b efficacy data exceeds expectations, offering a catalyst for a rebound.
Key entities
- CompanyCocrystal Pharma, Inc.
Biopharmaceutical company developing norovirus vaccine candidate CDI-988.
